Your browser is no longer supported. Please, upgrade your browser.
Settings
RCUS Arcus Biosciences, Inc. daily Stock Chart
RCUS [NYSE]
Arcus Biosciences, Inc.
Index- P/E- EPS (ttm)-2.10 Insider Own0.40% Shs Outstand47.20M Perf Week-4.11%
Market Cap528.17M Forward P/E- EPS next Y-2.26 Insider Trans- Shs Float33.43M Perf Month-6.67%
Income-49.60M PEG- EPS next Q-0.35 Inst Own50.10% Short Float3.75% Perf Quarter3.61%
Sales8.40M P/S62.88 EPS this Y-12.40% Inst Trans23.54% Short Ratio9.23 Perf Half Y-20.19%
Book/sh23.59 P/B0.47 EPS next Y-41.20% ROA-17.10% Target Price21.40 Perf Year-36.82%
Cash/sh5.44 P/C2.06 EPS next 5Y- ROE-19.80% 52W Range8.57 - 17.60 Perf YTD3.90%
Dividend- P/FCF- EPS past 5Y- ROI-23.40% 52W High-36.41% Beta-
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin- 52W Low30.57% ATR0.80
Employees108 Current Ratio15.30 Sales Q/Q23.10% Oper. Margin- RSI (14)47.55 Volatility6.93% 6.71%
OptionableYes Debt/Eq0.00 EPS Q/Q-289.30% Profit Margin- Rel Volume0.64 Prev Close11.86
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 Payout- Avg Volume135.94K Price11.19
Recom1.40 SMA20-4.98% SMA503.09% SMA200-7.70% Volume87,617 Change-5.65%
Oct-09-18Initiated Wedbush Outperform $22
Apr-09-18Initiated Leerink Partners Outperform $21
Apr-09-18Initiated Goldman Neutral $18
Apr-09-18Initiated Citigroup Buy $18
Mar-15-19 11:37AM  Infinity Inks Deal With Roche for Phase II Study of IPI-549 Zacks
Mar-05-19 04:10PM  Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates Business Wire
Feb-28-19 08:30AM  Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting Business Wire
Feb-13-19 04:10PM  Arcus Biosciences Announces Participation at Upcoming Investor Conference Business Wire +7.20%
Jan-04-19 04:34PM  Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today Motley Fool -14.11%
08:30AM  Arcus Biosciences Announces Transition of Chief Financial and Operating Officer Business Wire
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals
Dec-05-18 10:35AM  This year's Bay Area IPO batch remains up 44% despite market turbulence American City Business Journals
Nov-16-18 08:55AM  Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-09-18 07:30AM  Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting Business Wire
Nov-08-18 04:05PM  Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates Business Wire +5.15%
Nov-01-18 04:05PM  Arcus Biosciences Announces Participation at Three Investor Conferences in November Business Wire +5.27%
Oct-22-18 08:30AM  Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors Business Wire
Oct-10-18 12:25PM  Do You Know Who Else Invests In Arcus Biosciences Inc (NYSE:RCUS)? Simply Wall St.
Oct-08-18 06:40PM  Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress Business Wire -6.94%
Oct-02-18 04:30PM  Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting Business Wire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals
Sep-20-18 04:05PM  Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
Aug-29-18 04:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $280,407 of Shares GuruFocus.com -6.45%
Aug-24-18 08:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $124,937 of Shares GuruFocus.com
Aug-22-18 04:05PM  Arcus Biosciences Announces Participation at Two Investor Conferences in September Business Wire
Aug-21-18 10:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $117,717 of Shares GuruFocus.com
Aug-16-18 07:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $358,989 of Shares GuruFocus.com
Aug-06-18 04:05PM  Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates Business Wire
Aug-01-18 04:05PM  Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Jul-30-18 08:00AM  Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody Business Wire
Jul-17-18 08:00AM  Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers Business Wire
Jul-12-18 05:00PM  Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories Business Wire
Jun-26-18 08:30AM  Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies PR Newswire
08:30AM  Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies Business Wire
Jun-12-18 07:00AM  Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer Business Wire
Jun-11-18 07:30AM  Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations Business Wire
May-29-18 04:10PM  Arcus Biosciences Announces Participation at Upcoming Investor Conference Business Wire
May-18-18 08:59PM  Does Arcus Biosciences Incs (NYSE:RCUS) -120.96% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
May-09-18 04:10PM  Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates Business Wire +6.18%
May-03-18 10:17AM  Fresh $668 million biotech venture fund aims to quench hunger for data American City Business Journals
Apr-17-18 09:00AM  Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting Business Wire
Apr-09-18 05:53PM  In fresh IPO's 77 percent fall, another warning sign for biotech investors American City Business Journals
Apr-06-18 11:19AM  Peninsula anti-aging drug company files for $85M IPO American City Business Journals
Mar-19-18 05:27PM  Arcus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-15-18 04:10PM  Arcus Biosciences Announces Five Abstracts Accepted for Presentation at AACR 2018 Annual Meeting Business Wire
11:00AM  Cancer-fighting East Bay company upsizes IPO, raises $120 million American City Business Journals
Mar-14-18 05:53PM  Arcus Biosciences Announces Pricing of Initial Public Offering Business Wire
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.